AAEAAQAAAAAAAAUAAAAAJDMwZmQ0NGEzLWE2Y2ItNGU4My1hYmYzLTQ2YmMyODBjMjQ4OQ.png

Active Implants SUN Clinical Trial for Persistent Knee Pain Now Underway in San Diego

Posted On June 8, 2017 By OrthoSpineNews In Sports Medicine /

June 07, 2017

SAN DIEGO–(BUSINESS WIRE)–Active Implants, a company that develops orthopedic implant solutions, today announced that the company’s SUN (Safety Using NUsurface®) trial is now underway in San Diego. Dr. Scott A. Hacker at Grossmont Orthopaedic Medical Group is the only physician in San Diego County – and the center is one of just 10 sites nationwide – participating in the SUN clinical trial to evaluate the investigational NUsurface Meniscus Implant (pronounced “new surface”) for the treatment of persistent knee pain caused by injured or deteriorating meniscus cartilage.

The meniscus is a tissue pad between the thigh and shin bones. Once damaged, the meniscus has a very limited ability to heal. Over 1 million partial meniscectomies to remove or repair a torn meniscus are performed in the U.S. every year, about the same as the total number of hip and knee replacement surgeries combined. However, many patients still experience persistent knee pain following meniscus surgery.

“Current treatments for meniscus-related chronic knee pain do not address the underlying biology of the knee pain,” Dr. Hacker said. “Injections and medications do provide temporary relief for some patients but are just masking the symptoms. We hope this study finds that the NUsurface implant addresses the underlying problem and gets rid of the discomfort, allowing patients to return to the leisure and work activities that had been hindered by pain.”

The SUN study will enroll approximately 120 patients as part of regulatory process to gain approval from FDA to sell the device in the U.S. All patients who meet study requirements and agree to enter the trial are offered the NUsurface Meniscus Implant as treatment. Treatment with NUsurface in the SUN trial is eligible for coverage by Medicare and some private insurance companies. To be eligible for the study, participants must be between the ages of 30 and 75 and have pain after medial meniscus surgery that was performed at least six months ago. To learn more about the SUN study, please visit http://sun-trial.com or call (844) 680-8951.

About the NUsurface® Meniscus Implant

The NUsurface® Meniscus Implant is an investigational treatment for patients with persistent knee pain following medial meniscus surgery. It is made from medical grade plastic and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissues. The NUsurface Meniscus Implant mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint. Clinical trials are underway in the U.S., Europe and Israel to verify the safety and effectiveness of the NUsurface Meniscus Implant.

About Active Implants

Active Implants, LLC develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle. Active Implants is privately held with headquarters in Memphis, Tennessee. European offices are in Driebergen, The Netherlands, with R&D facilities in Netanya, Israel. For more information, visit www.activeimplants.com.

CAUTION Investigational device. Limited by United States law to investigational use.

Contacts

Merryman Communications
Joni Ramirez, 323-532-0746
joni@merrymancommunications.com

Oska® Wellness Honored with MedTech Breakthrough Award

Posted On June 7, 2017 By OrthoSpineNews In Extremities, Sports Medicine, Top Stories /

CARLSBAD, CA, June 7, 2017 – Oska Wellness, a technology company committed to developing consumer health and wellness products, announced that its Oska Pulse has been selected as the “Best IoT Healthcare Wearable Device” award winner from MedTech Breakthrough, an independent organization that recognizes the top companies, technologies and products in the global health and medical technology market.

“All of us at Oska are excited to receive this award from MedTech, who have recognized Oska’s mission to provide non-invasive, drug-free pain management solutions,” said Greg Houlgate, Oska Wellness CEO. “This is an important industry recognition for our year-old company and our flagship device, Oska Pulse. We’re very grateful.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Patient Engagement, Electronic Health Records (HER), mHealth, Medical Devices, Medical Data and many more. This year’s program attracted more than 2,000 nominations from more than 10 countries. All nominations were evaluated by an independent panel of experts within the medical and health industry, including media, analysts, and technology executives.

“We are thrilled to recognize Oska Wellness with this well-deserved industry recognition for innovation in the health and medical technology field,” said James Johnson, managing director, MedTech Breakthrough. “For the millions of Americans that suffer from chronic pain, Oska Pulse is a compelling solution and the MedTech Breakthrough Award designation is a testament to the skill, ingenuity, and vision of the Oska Wellness team.”

Oska Pulse is a safe, easy-to-use, portable and wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain and increase mobility for people who have acute or chronic pain.

About Oska Wellness
Oska, Inc. is committed to developing health and wellness technology-driven products that assist individuals in living a more active, pain-free lifestyle. Oska Pulse utilizes patented eTec Pulse Technology that specifically optimizes Pulsed Electromagnetic Field (PEMF) therapeutic technology, similar to the PEMF therapies used in many clinical applications for accelerating the body’s ability to heal itself.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with more than 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition. The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

About MedTech Breakthrough
The MedTech Breakthrough Awards program is devoted to honoring excellence in medical and health related technology companies, products and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough MedTech companies and products in categories including Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Genomics, Medical Data, Healthcare Cybersecurity and more. For more information visit www.MedTechBreakthrough.com

ADD COUPON CODE “ORTHOSPINECO” FOR $55.00 OFF

READ MORE ABOUT OSKA HERE

Oska® Wellness Teams Up With Arizona Golf Association to Promote the Revolutionary Oska Pulse

Posted On June 6, 2017 By OrthoSpineNews In Extremities, Sports Medicine, Top Stories /

CARLSBAD, Calif., May 31, 2017 /PRNewswire/ — Oska Wellness, a technology company committed to developing innovative consumer health and wellness products, is partnering with the Arizona Golf Association to promote Oska Pulse, a breakthrough wearable electromagnetic field device that eases pain. The AGA is comprised of more than 400 clubs and 75,000 members.

“I used Oska Pulse both prior to and after my hip surgery last year,” said Ed Gowan, Executive Director of the AGA. “We’re always interested in bringing new products and options to Arizona Golf members. If they can use Oska Pulse to play one more round, then we’re all for recommending it to our community.”

Oska Pulse is a safe, easy-to-use, wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain and increase mobility for people who have acute or chronic pain.

“I met Ed Gowan in 2010 while in the golf industry and am delighted to forge an official relationship with the Arizona Golf Association,” said Steve Collins, COO of Oska Wellness. “The AGA shares our mission for new ways to provide non-invasive, drug-free pain management solutions. Many golfers have told us that they’ve had to cut back on playing due to elbow, hip, wrist, knee, back pain and more. Those who have used Oska Pulse now view the device as just as important to managing their aches and pains as a putter or a driver is to his or her game.”

The Arizona Golf Association was founded in 1923 as a small group of golfers who got together to run the annual Amateur Championship. The AGA is a volunteer-based organization directed by amateur golfers, dedicated to promoting the game of golf, and providing valuable benefits and services to its members.

During the PGA Merchandise Show in January, Oska Wellness introduced Oska Pulse, a hands-free device that employs safe Pulsed Electromagnetic Field (PEMF) therapeutic technology to help people enjoy more active, pain-free and drug-free lives. Subsequently, Oska Pulse was named “best in show” by top golf publications, including Golf Digest.

CONTACT:
Robin Carr, Oska, Inc.
415-971-3991
162247@email4pr.com

ADD COUPON CODE “ORTHOSPINECO” FOR $55.00 OFF

READ MORE ABOUT OSKA HERE

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oska-wellness-teams-up-with-arizona-golf-association-to-promote-the-revolutionary-oska-pulse-300465961.html

Dr. Brian Badman is First and Only Indiana Shoulder Surgeon to Offer Breakthrough Treatment for Rotator Cuff Tears

Posted On June 6, 2017 By OrthoSpineNews In Extremities, Sports Medicine /

INDIANAPOLIS, INDIANA (PRWEB) JUNE 03, 2017

American Health Network today announced that Dr. Brian Badman is the first and only shoulder surgeon in Indiana to treat patients suffering from rotator cuff disease using the Rotation Medical Bioinductive Implant – a new technology that helps tendons heal through the induction of new tissue growth, potentially helping patients resume normal activities quicker than traditional treatment and reducing the likelihood of further degeneration or re-tears.

The minimally invasive system is designed as a new option for people suffering from rotator cuff tendon tears in the shoulder joint, which affect more than 4 million people annually in the U.S. and are the most common source of shoulder pain and disability.

“Rotator cuff injury is common, and many patients avoid surgery because they hear about painful, lengthy postoperative rehabilitation and time away from work,” said Dr. Brian Badman. “The Rotation Medical Bioinductive Implant, which is about the size of a postage stamp, is inserted through a small incision during a minimally invasive arthroscopic outpatient procedure. The Bioinductive Implant induces the formation of new tendinous tissue over the surface of the tendon, resulting in a thicker tendon. Depending on their stage of rotator cuff disease, the Bioinductive Implant can provide patients a range of potential benefits, including shorter rehabilitation, faster recovery, prevention or slowing of disease progression, healing of partial-thickness tears, and decreased risk of developing a subsequent tear.” Several prominent orthopedic shoulder surgeons across the country have helped pioneer this technology including Dr. Jeff Abrams at Princeton and Dr. Buddy Savoie at Tulane University.

Rotator cuﬀ tears are most often caused by chronic wear and tear with degeneration of the tendon. Rotator cuff tears can also occur in people who repeatedly perform overhead motions in their jobs or sports. In fact, more than 50 percent of people over age 60 have symptoms related to rotator cuff partial to full tearing of the tendon. Because traditional treatments do not address the poor quality of the underlying tendon tissue, a significant number of these tendons often develop into larger, more painful and debilitating tears and/or re-tears due to continuing degeneration of the torn tendon. The Bioinductive Implant allows surgeons to intervene early and potentially prevent disease progression by augmenting and healing the tendon before the injury worsens.

The Bioinductive Implant, manufactured by Rotation Medical, is suitable for most rotator cuff disease, from small partial-thickness tears to massive full-thickness tears. The Bioinductive Implant is derived from bovine Achilles tendon and gradually absorbs within six months, leaving a layer of new tendon-like tissue to biologically augment the existing tendon. This treatment can be used for both previously treated and untreated patients. Introduced to the market in 2014, the technology has been used in thousands of rotator cuff procedures in the U.S.

For more information, please visit Indyshoulder.com or to schedule an appointment with Dr. Badman, please call 317-208-3866.

About Dr. Badman
Dr. Badman grew up in South Bend, Indiana. He completed his orthopedic residency training at the University of Florida-Gainesville in 2005 and finished a shoulder and elbow fellowship at the Florida Orthopedic Institute in Tampa in 2006. Dr. Badman joined American Health Network (AHN) in 2011 as the founding member of AHN’s Bone & Spine group. He has subspecialty interest in shoulder and elbow disorders, with specialty training in arthroscopic rotator cuff repair, shoulder instability, total shoulder arthroplasty, reverse shoulder arthroplasty and proximal humeral fracture fixation. He is a member of the American Shoulder and Elbow Society and is only the fourth person from Indiana to be inducted into this prestigious international group of shoulder specialists. Over the past several years, Dr. Badman has consistently been one of the busiest reconstructive shoulder surgeons in the state, performing more than 150 replacement surgeries per year (total and reverse) and over 250 arthroscopic rotator cuff repairs annually.

About American Health Network’s Bone & Spine Group
American Health Network’s bone & spine physicians deal with diagnosis and treatment of diseases and injuries of the musculo-skeletal system, which includes bones, joints, muscles, ligaments, and tendons. The group provides fully integrated state-of-the-art care from diagnosis and treatment to rehabilitation. For more information, visit http://www.indyboneandspine.com

AAEAAQAAAAAAAAeFAAAAJGRkMTcxZDUwLWNlZGEtNDBlYS04MjA4LTE2MWI1NTE1OTA2NQ.jpg

Oska® Wellness Teams With MyTPI to Promote Oska Pulse

Posted On June 5, 2017 By OrthoSpineNews In Extremities, Sports Medicine /

CARLSBAD, Calif., May 17, 2017 /PRNewswire/ — Oska Wellness, a technology company committed to developing innovated consumer health and wellness products, is partnering with MyTPI to promote Oska Pulse, a breakthrough wearable electromagnetic field device that eases pain. MyTPI has the largest collection of golf-specific health, fitness and swing advice on the Internet.

“We’re excited to be working with MyTPI, sharing our mission for new ways to provide non-invasive, drug free pain management solutions,” said Greg Houlgate, CEO of Oska Wellness. “We’ve heard from many golfers who have had to cut back on playing due to pain. But thanks to the use of Oska Pulse, golfers can play one more round, pain free. Oska Pulse is a smart, safe, easy-to-use, wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain, and increase mobility for people who have acute or chronic pain.”

During the PGA Merchandise Show in January, Oska Wellness unveiled the Oska Pulse — a small, portable, hands-free device that employs safe Pulsed Electromagnetic Field (PEMF) therapeutic technology, a longtime therapy used by medical practitioners to help people enjoy more active, pain-free and drug-free lives. Subsequently, Oska Pulse was named “best in show” by several leading golf publications, including Golf Digest.

“I’ve used Oska Pulse and got great results with mobility and pain relief from this device,” said David Phillips, co-founder of TPI. “Our partnership with Oska Wellness will allow us be able to promote Oska Pulse to our leadership team, our affiliates, and our athletes. I’m a total believer in this product and I look forward to recommending it to our community.”

Phillips also said there are several ways to use the device. “After a round of golf, if you feel lower back pain or perhaps you have some wrist tendonitis,” he said. “Or prior to play, if you feel a little tightness in the morning. Use Oska Pulse on your way to the course.” Developed by the experts at the Titleist Performance Institute, MyTPI.com delivers advanced golf-specific information from experts on six continents and 62 countries.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with over 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition. The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

ADD COUPON CODE “ORTHOSPINECO” FOR $55.00 OFF

READ MORE ABOUT OSKA HERE

CONTACT:

Robin Carr, Oska, Inc.
415-971-3991
160282@email4pr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oska-wellness-teams-with-mytpi-to-promote-oska-pulse-300459069.html

Oska® Pulse is a “Best Product” Award Winner at ING Conference

Posted On June 5, 2017 By OrthoSpineNews In Extremities, Sports Medicine, Top Stories /

CARLSBAD, CA, June 1, 2017 – Oska Pulse, a breakthrough wearable electromagnetic field device that eases pain, was recently named “Best Product” at the 27^th Annual ING Spring Conference. Oska Pulse, the flagship product from Oska Wellness, received the award last month at the World Golf Village & Hall of Fame in St. Augustine, FL.

The ING Spring Conference is an annual gathering of media and golf industry executives conducted by the non-profit networking organization, the International Network of Golf. A group of 130 industry executive and media were in attendance at this years’ event, held May 21- 24. The Oska Pulse and the Knuth Golf High Heat fairway metals tied in voting by attendees who chose their favorite products which were demoed at the conference.

“We are thrilled to be honored by the folks who attended the ING Conference and who recognize Oska’s mission to provide non-invasive, drug free pain management solutions,” said Greg Houlgate, CEO of Oska Wellness. “It was an inspirational week at the conference, and we heard from golfers who deal with elbow, hip, wrist, knee, back pain and more. With Oska Pulse, golfers can play another round — pain free.”

During the PGA Merchandise Show in January, Oska Wellness introduced Oska Pulse, a hands-free device that employs safe Pulsed Electromagnetic Field (PEMF) therapeutic technology to help people enjoy more active, pain-free and drug-free lives. Oska Pulse was named “best in show” by top golf media outlets who attended, including Golf Digest, Golf Channel, and TravelingGolfer.net.

ADD COUPON CODE “ORTHOSPINECO” FOR $55.00 OFF

READ MORE ABOUT OSKA HERE

AAEAAQAAAAAAAAIiAAAAJGI3ODJjOTU4LTAwMDEtNDIyMC1iYTZiLThjNTlhMTY2NTZkOA-1.jpg

OrthoMemphis Performs First Meniscus Replacement in Tennessee with NUsurface® Implant

Posted On May 23, 2017 By OrthoSpineNews In Sports Medicine /

May 23, 2017 09:00 AM Eastern Daylight Time

MEMPHIS, Tenn.–(BUSINESS WIRE)–OrthoMemphis and Active Implants, a Memphis-based company that develops orthopedic implant solutions, today announced that the first meniscus replacement procedure in Tennessee was successfully performed.

Dr. Randall Holcomb, sports medicine orthopaedic surgeon and president of OrthoMemphis, was the surgeon selected for the study due to his 30 years of expertise in area of cartilage restoration and transplantation. OrthoMemphis is the only center in Tennessee – and just one of 10 sites nationwide – participating in the VENUS (Verification of the Effectiveness of the NUsurface® System) clinical trial, which is enrolling patients with persistent knee pain after loss of meniscus cartilage to assess the safety and effectiveness of the investigational NUsurface Meniscus Implant compared to non-surgical standard of care.

The meniscus is a tissue pad between the thigh and shin bones. Once it is damaged, the meniscus has a very limited ability to heal, and therefore meniscus surgery is performed to remove the torn painful portion of the meniscus. Over 1 million partial meniscectomies are performed in the U.S. every year, more than the total number of hip and knee replacement surgeries combined. While partial meniscectomy surgery is tremendously successful, there is still a subset of patients that continue to experience pain following meniscal surgery. These patients tend to have deteriorating meniscus cartilage, which remains painful and can evolve into arthritis requiring a total knee replacement.

The first patient to receive the NUsurface Meniscus Implant in Tennessee is Memphis resident Dr. Tim Goldsmith. He suffered a knee injury two years ago while practicing twisting lunges during a workout session. This injury led the 60-year-old to undergo alternative treatments to treat the pain, including muscle strengthening physical therapy, injections to relieve pain and finally a partial meniscectomy on his left knee. However, he continued to have consistent knee pain on a daily basis that impacted any activity – from playing golf and interval workout training classes to simply walking up and down stairs.

“There are few options for patients who experience persistent knee pain following meniscus surgery,” Dr. Holcomb said. “We hope the NUsurface implant will act as an artificial meniscus to alleviate their pain and hopefully prevent the onset of degenerative joint disease. Although at this time we cannot make the claim, the NUsurface device may be the solution to slowing down or preventing degenerative arthritis associated with meniscal injuries.”

Dr. Holcomb implanted the device in April 2016 through a small incision in Goldsmith’s knee. Goldsmith was able to quickly return to his work as chief clinical officer at Youth Villages, a private nonprofit dedicated to helping thousands of emotionally and behaviorally troubled children and their families live successfully. Following the full six-week physical therapy regimen with OrthoMemphis’ Steven Chipman,Goldsmith also resumed his favorite pastimes, including golf, spin classes, and interval strength and resistance training. Since his surgery, Goldsmith’s knee has been stable and he has continued his active lifestyle.

“Prior to receiving the NUsurface Meniscus Implant, I felt like I was out of options and had resigned myself to living with pain and waiting for eventual knee replacement,” Goldsmith said. “Now, I am not only rid of the knee pain, but am also experiencing better mobility and flexibility – this gives me hope that I will have the ability to stay as active as I’d like to be for as long as I can.”

The NUsurface Meniscus Implant is inserted into the knee joint through a small incision, and patients typically can go home on the same day of the operation. After surgery, they undergo a six-week rehabilitation program. NUsurface has been used in Europe since 2008 and Israel since 2011.

About the Clinical Trial

As part of the process to gain regulatory approval in the U.S., the VENUS (Verification of the Effectiveness of the NUsurface® System) study will enroll approximately 130 patients at orthopedic centers in the U.S., Europe and Israel. Sites in the U.S. include Indiana (Indianapolis), Massachusetts (Boston), New York (Albany, Rochester and New York), North Carolina (Durham), Ohio (Columbus), Tennessee (Memphis) and Virginia (Richmond). Participants who meet study requirements and agree to enter the trial are randomized to receive either the NUsurface device or non-surgical treatment, which is the current standard of care for patients with persistent knee pain following meniscus surgery. To be eligible for the study, participants must be between the ages of 30 and 75 and have pain after medial meniscus surgery that was performed at least six months ago. To learn more about the VENUS study, please call (844) 680-8951 or visit www.meniscus-trial.com.

About the NUsurface® Meniscus Implant

In the U.S., the NUsurface® Meniscus Implant, from Active Implants LLC, is an investigational treatment for patients with persistent knee pain following medial meniscus surgery. The NUsurface Meniscus Implant is made from medical grade plastic and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissue. The NUsurface device mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint. It is inserted into the knee joint through a small incision, and patients typically can go home soon after the operation. After surgery, patients undergo a six-week rehabilitation program. The NUsurface device has been used clinically in Europe since 2008 and Israel since 2011.

About OrthoMemphis

OrthoMemphis’ team of 18 doctors provides surgical and non-surgical treatment in general orthopedic and subspecialty areas of sports medicine, spine, hand, foot & ankle, hip & knee, total joint replacement, treatments of bone and soft tumors of the extremities (benign and malignant) in children and adults, and workers’ compensation injuries. Fellowship trained surgeons provide expert care in each subspecialty. For more information, go to http://www.orthomemphis.com/.

About Active Implants

Active Implants, LLC develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle. Active Implants is privately held with headquarters in Memphis, Tennessee. European offices are in The Netherlands, with R&D facilities in Israel. For more information, visit www.activeimplants.com.

CAUTION Investigational device. Limited by United States law to investigational use.

Contacts

Merryman Communications
Joni Ramirez, 323-532-0746
joni@merrymancommunications.com

Stryker and AlloSource announce collaboration to distribute biologics for use in sports medicine procedures

Posted On May 18, 2017 By OrthoSpineNews In Biologics, Sports Medicine /

DENVER, May 18, 2017 /PRNewswire-USNewswire/ — Today at the 2017 Annual Arthroscopy Association of North America (AANA) Meeting (booth #109), Stryker’s Sports Medicine business and AlloSource^® formally announced their collaboration to provide high quality, innovative biologics for use in sports medicine procedures. This collaboration is driven by the companies’ combined commitment to better serve their customers, help patients in need and fully honor the gift of tissue donation.

“We believe biologics will play a critical role in advancing the field of Sports Medicine, so we are very excited about the opportunity to collaborate with AlloSource given their history of quality and innovation,” said Matt Moreau, Vice President & General Manager of Stryker’s Sports Medicine business. “The collaboration between Stryker and AlloSource will enable us to combine our unique areas of expertise to develop new ways to improve patient outcomes.”

Through the collaboration, Stryker’s Sports Medicine nationwide sales force will distribute AlloSource biologics for use in a variety of sports medicine procedures.

“Deepening our relationship with Stryker through this sports medicine collaboration will help us further advance patient healing and honor our tissue donors by getting biologics in the hands of more surgeons,” said Kerr Holbrook, AlloSource Chief Commercial Officer. “We look forward to working and growing together.”

For more information, please visit Stryker’s website or AlloSource’s website.

About Stryker
Stryker is one of the world’s leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world. Please contact us for more information at www.stryker.com.

About AlloSource
AlloSource is one of the largest nonprofit cellular and tissue networks in the country, offering more than 200 types of precise cartilage, cellular, bone, skin and soft-tissue allografts to advance patient healing. For more than 20 years, AlloSource’s products have bridged the proven science of allografts with the advanced technology of cells, offering life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. As the world’s largest processor of cellular bone allografts, fresh cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource delivers unparalleled expertise and service to its growing network of surgeons, partners, and the country’s most reputable organ procurement organizations. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org or our educational website, allograftpossibilities.org.

Media contacts
Jon Zimmer, Stryker, jon.zimmer@stryker.com
Megan Duggan, AlloSource, mduggan@allosource.org

SOURCE AlloSource

Orthonika accelerates development of total meniscus replacement and secures additional funding

Posted On May 17, 2017 By OrthoSpineNews In Financial, Sports Medicine, Top Stories /

London, UK, 15th May 2017 / Orthonika Limited, a spin-out from Imperial College London, is pleased to announce success in securing funding for development of its novel synthetic total knee meniscus replacement. The company has closed a second round of investment of £675,000 from a group of angel investors alongside a Biomedical Catalyst award and an Industrial Challenge award. The funding is being used to accelerate progress on biomechanical testing and carry out a pre-clinical pilot trial.

Dr Mario Alberto Accardi, Co-Founder and Chief Executive Officer, commented “We are delighted to have raised the funds to bring this revolutionary treatment for meniscus injury into a pre-clinical pilot trial. We are very grateful to our angel investors and Innovate UK for their support.”

Dominique Kleyn, Co-Founder and Chief Operating Officer, added “This investment demonstrates a strong endorsement of our progress in developing a novel solution for meniscus injury and allows us to cement our network of collaborators and suppliers.”

Orthonika brings design and development expertise to exploit a novel approach for the replacement of a damaged meniscus, restoring knee biomechanics and allowing patients to return to an active lifestyle. The goal is to advance the meniscus replacement into a product and obtain regulatory approval for its clinical application.

Ends

For further information, contact:

Orthonika

Dr Mario Alberto Accardi
CEO and Co-Founder
E: ma.accardi@orthonika.com

Dominique Kleyn
COO and Co-Founder
E: d.kleyn@orthonika.com

Media Relations, Sciad Communications

Deborah Cockerill
Managing Partner
E: deborah@sciad.com
T: +44 (0)20 7470 8801

Notes to Editors

About Orthonika Limited:
Orthonika is a spin-out from Imperial College London founded in 2015, developing an anatomical total meniscus replacement for the knee joint. Orthonika’s revolutionary meniscus implant accurately mimics the natural structure of meniscal tissue replicating its ‘structure-function’ relationship. It is designed to restore knee biomechanics and allow patients to return to an active lifestyle, an option currently not available to patients with severe meniscus injury hence fulfilling a gap of high unmet clinical need. For further information visit www.orthonika.com.

About Innovate UK:
Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information visit www.innovateuk.gov.uk.

About meniscus injury:
Meniscus injury is the most frequent orthopaedic surgical intervention with meniscus-related operations accounting for up to 50% of all knee surgeries with an average of 1.7m total surgeries performed each year in the EU and U.S. Despite this prevalence, today’s standard of care for a severely damaged meniscus is partial or total meniscectomy (removal) with no total meniscus replacement currently available on the market. Removal of the meniscus is well understood to be a major risk factor for osteoarthritis (OA) a chronic and debilitating condition, with an estimated 50% of partial meniscectomy patients being diagnosed with OA as a result.

Category:

Press Release

Arthroscopic Surgery Doesn’t Help With Arthritis Knee Pain

Posted On May 12, 2017 By OrthoSpineNews In Sports Medicine, Top Stories /

Carmen Heredia Rodriguez, Kaiser Health News – May 11, 2017

An international panel of surgeons and patients has challenged the effectiveness of one of the most common orthopedic procedures and recommended strongly against the use of arthroscopic surgery for patients with degenerative knee problems.

The guidelines, published Wednesday in the journal BMJ, reviewed 13 studies involving nearly 1,700 patients and found the surgery did not provide lasting pain relief or improve function for most of them. Those studies compared the surgery with a variety of options, including physical therapy, exercise and even placebo surgery.

Fewer than 15 percent of patients felt an improvement in pain and function three months after the procedure, and that those effects disappeared after one year, the review found. In addition, the surgery exposed patients to “rare but important harms,” such as infection.

Casey Quinlan, 64, who had the surgery in 2003 and was on the panel issuing the guidelines, said her orthopedist told her the procedure would not only help restore mobility in her knee after a nasty ski accident but also improve her arthritis.

Quinlan, of Richmond, Va., said the procedure did not deliver, since her arthritis remained unchanged. “It was not what I was told to expect,” she says.

In an arthroscopic knee surgery, physicians make several small incisions around the joint and insert a tiny camera that allows them to see inside the knee as well as insert small instruments to correct problems they identify. Often the surgery is performed to remove part of a damaged meniscus, a disc of cartilage that helps cushion the knee.

The panel said meniscal tears “are common, usually incidental findings, and unlikely to be the cause of knee pain, aching or stiffness.”

READ THE REST HERE

Sports Medicine

Contacts

Contacts

Related Links

Ends

For further information, contact:

Notes to Editors